« Back
Home /
Tovinontrine

Tovinontrine

Item no.	HY-109193-25mg
Manufacturer	MedChem Express
CASRN	2062661-53-2
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.83
Citations	[1]James G McArthur, et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020 Mar;105(3):623-631.
Smiles	O=C1C2=CN=C(C3CCOCC3)N2C=C([C@@H]4CN(CC5=NC=CC=N5)C[C@H]4C)N1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	IMR-687
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Phosphodiesterase (PDE)
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	394.47
Product Description	Tovinontrine (IMR-687) is a highly potent and selective phosphodiesterase-9 (PDE9) inhibitor specifically for the treatment of sickle cell disease. IC50s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively[1].
Manufacturer - Research Area	Cardiovascular Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Metabolic Enzyme/Protease
Isoform	PDE1; PDE5; PDE9
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-109193-25mg-safety-datasheet.pdf